Literature DB >> 18382646

Alemtuzumab and natalizumab: the monoclonal antibody story continues.

Bl Johnston1, Jm Conly.   

Abstract

Entities:  

Year:  2006        PMID： 18382646      PMCID： PMC2095094          DOI： 10.1155/2006/876252

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN： 1712-9532            Impact factor:   2.471


× No keyword cloud information.
  31 in total

1.  Natalizumab effects on immune cell responses in multiple sclerosis.

Authors:  Masaaki Niino; Caroline Bodner; Marie-Lune Simard; Sudabeh Alatab; Dawn Gano; Ho Jin Kim; Manuela Trigueiro; Denise Racicot; Christine Guérette; Jack P Antel; Alyson Fournier; Francois Grand'Maison; Amit Bar-Or
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

2.  Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.

Authors:  R Lamba; G Carrum; G D Myers; C M Bollard; R A Krance; H E Heslop; M K Brenner; U Popat
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

3.  Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.

Authors:  R M Y Barge; C W J Starrenburg; J H F Falkenburg; W E Fibbe; E W Marijt; R Willemze
Journal:  Bone Marrow Transplant       Date:  2006-06       Impact factor: 5.483

4.  Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.

Authors:  Stanley I Martin; Francisco M Marty; Karen Fiumara; Steven P Treon; John G Gribben; Lindsey R Baden
Journal:  Clin Infect Dis       Date:  2006-05-17       Impact factor: 9.079

5.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

Authors:  B K Kleinschmidt-DeMasters; Kenneth L Tyler
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

6.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

Review 7.  The role of alemtuzumab in the management of T-cell malignancies.

Authors:  Claire Dearden
Journal:  Semin Oncol       Date:  2006-04       Impact factor: 4.929

Review 8.  Emerging monoclonal antibody therapies for multiple sclerosis.

Authors:  Bruce Cree
Journal:  Neurologist       Date:  2006-07       Impact factor: 1.398

9.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

10.  Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

Authors:  Tarek A Yousry; Eugene O Major; Caroline Ryschkewitsch; Gary Fahle; Steven Fischer; Jean Hou; Blanche Curfman; Katherine Miszkiel; Nicole Mueller-Lenke; Esther Sanchez; Frederik Barkhof; Ernst-Wilhelm Radue; Hans R Jäger; David B Clifford
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
View more
  1 in total

Review 1.  The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy.

Authors:  Peter O Behan; Abhijit Chaudhuri
Journal:  Inflammopharmacology       Date:  2010-09-24       Impact factor: 5.093
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.